Kardigan develops cardiovascular therapeutics to treat heart disease.
$400MIPO
Investor undisclosed
A $400M cardiology IPO in mid-2026 signals that late-stage biotech can still access public markets if they have clinical validation—but the bar is high and the window is narrow. If you're building in adjacent therapeutic areas (metabolic disease, pulmonary hypertension), this shows investors will fund the path to Phase 3 data, but you'll need to prove efficacy before the IPO window closes.